Keyphrases
Adverse Events
25%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
24%
Antitumor Activity
15%
Bevacizumab
17%
Breast Cancer
61%
Brentuximab Vedotin
24%
Cancer Treatment
13%
Cancer Types
13%
Carboplatin
19%
Cetuximab
14%
Chemotherapy
70%
Chronic Lymphocytic Leukemia
13%
Circulating Tumor DNA (ctDNA)
23%
Cisplatin
23%
Clinical Outcomes
22%
Clinical Trials
41%
Colorectal Cancer
23%
Colorectal Liver Metastases
13%
Complete Response
22%
Confidence Interval
57%
Cyclophosphamide
16%
Diffuse Large B-cell Lymphoma (DLBCL)
25%
Disease Progression
17%
Disease-free Survival
13%
Docetaxel
22%
Dose Escalation
16%
Doxorubicin
27%
Follicular Lymphoma
27%
Gemcitabine
23%
Glioblastoma
17%
Hazard Ratio
30%
Head-and-neck Cancer
13%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
19%
High Risk
17%
Hodgkin Lymphoma
19%
Human Epidermal Growth Factor Receptor 2 (HER2)
16%
Immune Checkpoint Inhibitors
21%
In Cancer
26%
Leukemia
13%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
29%
Lung Cancer
34%
Lymphoma
19%
Malignancy
13%
Mantle Cell Lymphoma
28%
Maximum Tolerated Dose
14%
Median Overall Survival
19%
Median Progression-free Survival
19%
Melanoma
19%
Metastasis
15%
Metastatic Breast Cancer
33%
Monotherapy
18%
Multiple Myeloma
13%
NCCN Guidelines
23%
Neoadjuvant
14%
Neutropenia
14%
Newly Diagnosed
13%
Non-Hodgkin Lymphoma
18%
Non-small Cell Lung Cancer (NSCLC)
67%
Objective Response Rate
18%
Older Adults
18%
Older Patients
14%
Oncology
21%
Overall Response Rate
20%
Overall Survival
87%
Paclitaxel
18%
Pancreatic Cancer
21%
Pancreatic Ductal Adenocarcinoma
18%
Partial Response
22%
Pembrolizumab
21%
Peripheral T-cell Lymphoma
15%
Phase I Study
18%
Phase II Study
67%
Phase II Trial
57%
Placebo
17%
Prednisone
13%
Previously Treated
16%
Programmed Death-ligand 1 (PD-L1)
25%
Progression-free Survival
59%
Radiation Therapy
26%
Radiotherapy
13%
Randomized Phase II Trial
17%
Relapsed or Refractory
43%
Resection
13%
Response Rate
16%
Rituximab
37%
Sarcoma
15%
Small Cell Lung Cancer
16%
Soft Tissue Sarcoma
13%
Solid Tumors
19%
Stable Disease
16%
Systemic Therapy
15%
T Cells
19%
Targeted Therapy
31%
Treatment Options
14%
Treatment-related Adverse Events
13%
Triple-negative Breast Cancer
22%
Tumor
100%
Tumor Cells
16%
Tumor Microenvironment
14%
United States
13%
Medicine and Dentistry
Adjuvant Chemotherapy
9%
Adverse Event
28%
Arm
29%
B Cell
12%
B-Cell Chronic Lymphocytic Leukemia
11%
B-Cell Lymphoma
9%
Bevacizumab
9%
Biological Marker
27%
Breast Cancer
90%
Brentuximab Vedotin
16%
Cancer
42%
Cancer Cell
16%
Cancer Therapy
15%
Carboplatin
11%
Carcinogenesis
13%
Cetuximab
9%
Chemoradiotherapy
14%
Circulating Tumor DNA
17%
Cisplatin
18%
Classical Hodgkin Lymphoma
11%
Clinical Trial
50%
Colorectal Carcinoma
16%
Colorectal Liver Metastasis
10%
Connective Tissue Cancer
20%
Cyclophosphamide
13%
Cytotoxic T-Cell
8%
Diffuse Large B-Cell Lymphoma
23%
Disease Exacerbation
9%
Disease Free Survival
11%
Diseases
95%
Doxorubicin
18%
Epidermal Growth Factor Receptor
13%
Estrogen Receptor
9%
Follicular Lymphoma
18%
Gemcitabine
15%
Glioblastoma
14%
Hazard Ratio
23%
Head and Neck Cancer
10%
Head and Neck Squamous Cell Carcinoma
15%
Health Care Cost
9%
Hematopoietic Cell
9%
Hodgkin's Lymphoma
25%
Hormone Therapy
13%
Human Immunodeficiency Virus
11%
Immune Checkpoint Inhibitor
16%
Immunotherapy
38%
Lung
9%
Lung Cancer
32%
Malignant Neoplasm
92%
Malignant Peripheral Nerve Sheath Tumor
9%
Mantle Cell Lymphoma
24%
Melanoma
25%
Metastatic Breast Cancer
22%
Metastatic Carcinoma
36%
Monotherapy
9%
Multiple Myeloma
11%
Neoadjuvant Chemotherapy
11%
Neoplasm
91%
Neurofibromatosis Type I
9%
Nivolumab
10%
Non Small Cell Lung Cancer
70%
Non-Hodgkin Lymphoma
23%
Oncology
41%
Overall Survival
88%
Paclitaxel
17%
Pancreas Adenocarcinoma
16%
Pancreas Cancer
17%
Pembrolizumab
19%
Peripheral T-Cell Lymphoma
14%
Phase II Trials
17%
Placebo
14%
Positron Emission Tomography
14%
Primary Tumor
10%
Prognostic Factor
9%
Programmed Death-Ligand 1
9%
Progression Free Survival
56%
Prostate Cancer
17%
Quality of Life
14%
Radiation Therapy
38%
Rectum Cancer
9%
Recurrent Disease
28%
Rituximab
32%
Small Cell Lung Cancer
17%
Soft Tissue Sarcoma
14%
Solid Malignant Neoplasm
16%
Squamous Cell Carcinoma
11%
Stem Cell Transplant
9%
Survival Rate
9%
Systematic Review
10%
Systemic Therapy
16%
T Cell
24%
Targeted Therapy
29%
Treatment Option
12%
Triple Negative Breast Cancer
17%
Tumor
61%
Tumor Cell
13%
Tumor Microenvironment
8%
Tumor Progression
14%
Vincristine
8%
Wart Virus
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
43%
Anemia
8%
Antitumor Activity
12%
Bendamustine
12%
Bevacizumab
15%
Biological Marker
23%
Bortezomib
9%
Breast Cancer
53%
Brentuximab Vedotin
12%
Carboplatin
19%
Carcinogenesis
12%
Castration Resistant Prostate Cancer
8%
Cetuximab
13%
Chemoradiation Therapy
15%
Chemotherapy
91%
Chronic Lymphatic Leukemia
10%
Circulating Tumor DNA
11%
Cisplatin
21%
Clinical Trial
43%
Colon Carcinoma
7%
Colorectal Carcinoma
15%
Combination Therapy
8%
Connective Tissue Cancer
9%
Cyclin Dependent Kinase 4
9%
Cyclophosphamide
19%
Diarrhea
10%
Diffuse Large B Cell Lymphoma
20%
Disease Exacerbation
13%
Disease Free Survival
8%
Diseases
84%
Docetaxel
21%
Doxorubicin
28%
Endocrine Therapy
9%
Epidermal Growth Factor Receptor
18%
Erlotinib
7%
Estrogen Receptor
8%
Etoposide
12%
Everolimus
7%
Follicular Lymphoma
22%
Gamma Urogastrone
7%
Gemcitabine
19%
Glioblastoma
15%
Head and Neck Squamous Cell Carcinoma
13%
Hodgkin Disease
15%
Hormone Receptor
8%
Immune Checkpoint Inhibitor
12%
Immunotherapy
22%
Irinotecan
8%
Lenalidomide
9%
Leukemia
10%
Liver Cell Carcinoma
7%
Lung Cancer
26%
Malignant Neoplasm
85%
Mantle Cell Lymphoma
19%
Maximum Tolerated Dose
12%
Melanoma
16%
Metastatic Breast Cancer
28%
Metastatic Colorectal Cancer
7%
Methotrexate
7%
Monotherapy
16%
Nausea
7%
Neoplasm
85%
Neutropenia
14%
Nivolumab
7%
Non Small Cell Lung Cancer
77%
Nonhodgkin Lymphoma
26%
Overall Survival
82%
Paclitaxel
31%
Palbociclib
9%
Pancreas Adenocarcinoma
12%
Pancreas Cancer
13%
Pembrolizumab
14%
Pemetrexed
9%
Peripheral T Cell Lymphoma
8%
Pharmacokinetics
15%
Phase I Trials
7%
Phase II Trials
27%
Phase III Trials
11%
Phosphatidylinositol 3 Kinase
7%
Placebo
18%
Prednisone
12%
Progression Free Survival
67%
Prostate Cancer
23%
Receptor
9%
Recurrent Disease
17%
Remission
13%
Renal Cell Carcinoma
8%
Rituximab
41%
Small Cell Lung Cancer
20%
Soft Tissue Sarcoma
11%
Solid Malignant Neoplasm
28%
Squamous Cell Carcinoma
8%
Survival Rate
11%
Temozolomide
7%
Thrombocytopenia
8%
Tolerability
11%
Transitional Cell Carcinoma
8%
Triple Negative Breast Cancer
12%
Tumor Growth
12%
Vincristine
12%